---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-314746"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:30:26.670340+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028

## Summary
- Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.
- Underwriters fully exercised option for additional 2,763,157 shares; total gross proceeds ~$402.5M.
- Closing expected Dec 11, 2025; pro forma shares outstanding ~187.7M.
- Cash runway extended into Q3 2028; excludes potential milestone payments from GSK collaboration.
- Jefferies, Leerink Partners, BofA Securities act as joint book-running managers.

## SEC filing metadata
- accession: 0001193125-25-314746
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525314746/0001193125-25-314746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525314746/d88507d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-314746
- JSON: https://secwatch.observer/filing/0001193125-25-314746.json
- Plain text: https://secwatch.observer/filing/0001193125-25-314746.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.